Necessary stem cell transplantation using myeloablative therapy for myelodysplastic syndrome with progression of genotypic abnormalities and TP 53 dysfunction in a young adult

A 14‐yr‐old male was admitted to our hospital with MDS and the chromosomal abnormality 45, XY ,der(5;17)(p10;q10). He rapidly developed karyotype abnormalities, accompanied by the loss of tumor suppressor gene TP 53 function. He suffered an early relapse after reduced‐intensity‐conditioning SCT and ultimately required myeloablative therapy before a second SCT . We consider that the analysis of TP 53 mutations is essential when planning the treatment of patients with MDS .